*Reliable Results refers to PROPEL family, based on Pilot, Advance II, and PROGRESS studies.
1 Data on file. N=80 in ITT population, with N=61 evaluable patients where both sinuses available for composite endpoint.
2 Primary results judged by independent reviewer.
3 Secondary endpoints judged by clinical investigators. P-values for secondary efficacy endpoints were adjusted for multiplicity. Green arrow indicates relative reduction 30 days following treatment.
The PROPEL sinus implants are intended for use after sinus surgery to maintain patency and to locally deliver steroid to the sinus mucosa: PROPEL for use in the ethmoid sinus, PROPEL Mini for use in the ethmoid sinus and frontal sinus opening, and PROPEL Contour for use in the frontal and maxillary sinus ostia. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implants in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For complete prescribing information see IFU at www.IntersectENT.com. Rx only.
The PROPEL® Contour implant, delivery system, and/or the use of the PROPEL® Contour implant/delivery system in a method may be covered by one or more U.S. and/or foreign patents, including U.S. Patent Nos. 7,544,192, 7,662,141, 7,662,142, 7,713,255, 7,951,133, 7,951,135, 8,109,918, 8,535,707, 8,585,731, 8,763,222, and 8,986,341. Other patent applications are pending. This page is intended to serve as notice under 35 U.S.C. § 287(a).